Mykofenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolatmofetil Accord, is an antimetabolite immunosuppressant presented as an intravenous formulation for use in organ transplantation and selected autoimmune diseases. It works by inhibiting lymphocyte proliferation to help prevent graft rejection and control immune‑mediated inflammation.

GNH USA supplies Mykofenolatmofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used to modulate immune responses in several clinical settings: - Prevention of acute organ transplant rejection: reduces the incidence of graft rejection by suppressing T‑cell activity. - Systemic lupus erythematosus: helps control disease activity and flares in patients with severe manifestations. - Vasculitis: contributes to disease control by limiting immune‑mediated vascular inflammation.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, sometimes leading to dehydration. - Vomiting: occasional emesis. - Abdominal pain: crampy discomfort. - Headache: transient mild headache. - Mild infections: increased susceptibility to common colds.

Serious or Rare Side Effects: - Severe infections: opportunistic or life‑threatening infections. - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy risk: increased incidence of certain cancers with long‑term use. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease. - Teratogenicity: fetal harm when exposure occurs during pregnancy.

Mycophenolate Mofetil requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in women of childbearing potential unless effective contraception is used. - Blood counts: monitor complete blood count regularly to detect leukopenia or anemia. - Liver function: assess hepatic enzymes periodically, especially in patients with pre‑existing liver disease. - Live vaccines: avoid administration while on therapy due to reduced immune competence. - Drug interactions: review concomitant medications for potential additive immunosuppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mycophenolate Mofetil can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid): - Antimetabolites (e.g., azathioprine): additive bone‑marrow suppression. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce drug exposure. - Live viral vaccines: increased risk of severe infection.

Moderate Interactions (Monitor Closely): - Antacids containing magnesium or aluminum: may decrease absorption. - ACE inhibitors or ARBs: potential for increased renal toxicity. - Cholesterol‑lowering agents (e.g., statins): heightened risk of myopathy. - Vaccines (non‑live): monitor immune response efficacy.